Health utility values associated with pharmaceutical treatment process attributes: a systematic review and meta-analysis
Abstract
Background: In cases where clinical efficacy and safety profiles are similar, patient preferences for the treatment process become a critical determinant of therapeutic adherence and health-related quality of life (HRQoL). However, current research on the utility of treatment process attributes (such as administration route, frequency, and time) show significant heterogeneity. Moreover, the results are often influenced by confounding factors, making it difficult to quantify their independent utility impact.
Objectives: This study aims to deconstruct prevalent confounding biases through a systematic review and multivariable meta-regression. The goal is to isolate the independent effects of various treatment process attributes on health utility values, thereby providing more precise evidence for pharmacoeconomic evaluations.
Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, this study systematically searched PubMed, Cochrane Library, Web of Science, and EBSCO databases for relevant English-language literature published up to December 2024. Original research reporting health utility values (on a 0-1 scale) associated with pharmaceutical treatment process attributes was included. Extracted disutility values, defined as Disutility=Utility - 1, were analyzed using random-effects models. Univariate, bivariate, and multivariable meta-regression models were constructed to control for key confounders, such as disease type…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.